Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform ...
- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight ...
Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012 DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% ...
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.
(RTTNews) - Bright Minds Biosciences Inc. (DRUG), a clinical-stage biotechnology company, announced that it will host a conference call and live webcast at 8:00 AM ET on January 6, 2026, to report ...
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing ...
TipRanks on MSN
Bright Minds Biosciences sets January 6 webcast for BMB-101 phase 2 topline results in drug-resistant absence seizures
Bright Minds Biosciences ( ($TSE:DRUG) ) has issued an update. On January 5, 2026, Bright Minds Biosciences announced plans to report topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results